Page last updated: 2024-11-05

decylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

decylamine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8916
CHEMBL ID109819
CHEBI ID166481
SCHEMBL ID20619
MeSH IDM0045891

Synonyms (59)

Synonym
bdbm50147566
CHEBI:166481
decyl-amine
n-decylamine
2016-57-1
ai3-52306
aminodecane
einecs 217-957-7
1-aminodecane
brn 1735220
kemamine p 190d
1-decylamine
hsdb 7324
monodecylamine
decylamine
inchi=1/c10h23n/c1-2-3-4-5-6-7-8-9-10-11/h2-11h2,1h
decan-1-amine ,
decane,1-amino
1-decanamine
decylamine, analytical standard
decylamine, 95%
decylamine, >=99.0% (gc)
D0033
1-decaneamine
CHEMBL109819 ,
NCGC00249022-01
AKOS009159300
unii-m9kkq6zzg9
m9kkq6zzg9 ,
4-04-00-00783 (beilstein handbook reference)
dtxcid902171
cas-2016-57-1
NCGC00256367-01
tox21_302938
dtxsid2022171 ,
NCGC00258855-01
tox21_201303
A814298
FT-0607343
decylamine [hsdb]
SCHEMBL20619
decyl amine
amine 10
n-c10h21nh2
amine-10
n-decyl amine
Q-200932
normal-decylamine
decanamine
mfcd00008149
decylamine, purum, >=98.0% (gc)
C93407
Q5493262
AMY21843
EN300-100309
STR11665
CS-W016217
SY011500
Z362810900

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Dose-response curves were developed for dilution series using fixed ratios between concentrations in toxic units of the compounds."( Joint action of chemicals in algal toxicity tests: influence of response level and dose-response regression model.
Chen, D; Christensen, ER; Kusk, KO; Nyholm, N, 2001
)
0.31
" The study was performed using three toxicity indices: additive index, sum of toxic units, and similarity parameter lambda."( Joint toxicity of similarly and dissimilarly acting chemicals to Daphnia magna at different response levels.
Christensen, ER; Kusk, KO; Merino-GarcĂ­a, D, 2003
)
0.32

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves were developed for dilution series using fixed ratios between concentrations in toxic units of the compounds."( Joint action of chemicals in algal toxicity tests: influence of response level and dose-response regression model.
Chen, D; Christensen, ER; Kusk, KO; Nyholm, N, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkylamineAny primary amine in which the substituent attached to nitrogen is an alkyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency6.11310.000714.592883.7951AID1259369
progesterone receptorHomo sapiens (human)Potency69.00830.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency69.00830.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency27.71440.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.97480.001530.607315,848.9004AID1224841
farnesoid X nuclear receptorHomo sapiens (human)Potency62.04480.375827.485161.6524AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency12.14750.000229.305416,493.5996AID743069
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency15.35530.000323.4451159.6830AID743065
heat shock protein beta-1Homo sapiens (human)Potency62.04480.042027.378961.6448AID743210
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dynamin-1Homo sapiens (human)IC50 (µMol)33.50003.15004.17335.0000AID63727
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
endocytosisDynamin-1Homo sapiens (human)
receptor-mediated endocytosisDynamin-1Homo sapiens (human)
endosome organizationDynamin-1Homo sapiens (human)
modulation of chemical synaptic transmissionDynamin-1Homo sapiens (human)
protein homooligomerizationDynamin-1Homo sapiens (human)
protein homotetramerizationDynamin-1Homo sapiens (human)
regulation of vesicle sizeDynamin-1Homo sapiens (human)
clathrin coat assembly involved in endocytosisDynamin-1Homo sapiens (human)
vesicle scissionDynamin-1Homo sapiens (human)
receptor internalizationDynamin-1Homo sapiens (human)
synaptic vesicle budding from presynaptic endocytic zone membraneDynamin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
RNA bindingDynamin-1Homo sapiens (human)
GTPase activityDynamin-1Homo sapiens (human)
protein bindingDynamin-1Homo sapiens (human)
GTP bindingDynamin-1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingDynamin-1Homo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate bindingDynamin-1Homo sapiens (human)
GDP bindingDynamin-1Homo sapiens (human)
protein kinase bindingDynamin-1Homo sapiens (human)
identical protein bindingDynamin-1Homo sapiens (human)
protein homodimerization activityDynamin-1Homo sapiens (human)
microtubule bindingDynamin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
photoreceptor inner segmentDynamin-1Homo sapiens (human)
plasma membraneDynamin-1Homo sapiens (human)
clathrin-coated pitDynamin-1Homo sapiens (human)
endocytic vesicleDynamin-1Homo sapiens (human)
chromaffin granuleDynamin-1Homo sapiens (human)
cell projectionDynamin-1Homo sapiens (human)
extracellular exosomeDynamin-1Homo sapiens (human)
photoreceptor ribbon synapseDynamin-1Homo sapiens (human)
presynapseDynamin-1Homo sapiens (human)
presynaptic endocytic zone membraneDynamin-1Homo sapiens (human)
glutamatergic synapseDynamin-1Homo sapiens (human)
membrane coatDynamin-1Homo sapiens (human)
plasma membraneDynamin-1Homo sapiens (human)
synapseDynamin-1Homo sapiens (human)
microtubuleDynamin-1Homo sapiens (human)
cytoplasmDynamin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID63727Concentration required against dynamin-1 GTPase activity of sheep brain.2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Long chain amines and long chain ammonium salts as novel inhibitors of dynamin GTPase activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (20.83)18.7374
1990's2 (8.33)18.2507
2000's9 (37.50)29.6817
2010's8 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.77 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index49.01 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]